MARY ROLLINS: Open Payments
NPI 1851968952 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,773 in 113 payments from 16 companies in 2025. Trend: 2023 $214 · 2024 $1,106 · 2025 $1,773
Food & beverage: $1,773
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $436 |
| Janssen Pharmaceuticals, Inc | 7 | $251 |
| Alkermes, Inc. | 17 | $227 |
| Vanda Pharmaceuticals Inc. | 14 | $172 |
| Otsuka America Pharmaceutical, Inc. | 12 | $168 |
| ABBVIE INC. | 12 | $143 |
| Almatica Pharma LLC | 4 | $84 |
| E.R. Squibb & Sons, L.L.C. | 5 | $79 |
| Braeburn Inc. | 2 | $38 |
| Biogen, Inc. | 2 | $37 |
Products named: CAPLYTA, SPRAVATO, REXULTI, ARISTADA, VRAYLAR, HETLIOZ, LOREEV XR, COBENFY.
Industry payments across KY — which companies pay providers there.
